AMERISAFE Earnings Calls
| Release date | Apr 22, 2026 |
| EPS estimate | $0.520 |
| EPS actual | $0.500 |
| EPS Surprise | -3.85% |
| Revenue estimate | 90.494M |
| Revenue actual | 88.5M |
| Revenue Surprise | -2.20% |
| Release date | Feb 25, 2026 |
| EPS estimate | $0.570 |
| EPS actual | $0.510 |
| EPS Surprise | -10.53% |
| Revenue estimate | 67.091M |
| Revenue actual | 70.055M |
| Revenue Surprise | 4.42% |
| Release date | Oct 29, 2025 |
| EPS estimate | $0.550 |
| EPS actual | $0.550 |
| Revenue estimate | 80.053M |
| Revenue actual | 81.984M |
| Revenue Surprise | 2.41% |
| Release date | Jul 24, 2025 |
| EPS estimate | $0.550 |
| EPS actual | $0.530 |
| EPS Surprise | -3.64% |
| Revenue estimate | 78.102M |
| Revenue actual | 81.088M |
| Revenue Surprise | 3.82% |
Last 4 Quarters for AMERISAFE
Below you can see how AMSF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 24, 2025 |
| Price on release | $43.58 |
| EPS estimate | $0.550 |
| EPS actual | $0.530 |
| EPS surprise | -3.64% |
| Date | Price |
|---|---|
| Jul 18, 2025 | $45.18 |
| Jul 21, 2025 | $44.09 |
| Jul 22, 2025 | $44.11 |
| Jul 23, 2025 | $44.00 |
| Jul 24, 2025 | $43.58 |
| Jul 25, 2025 | $46.23 |
| Jul 28, 2025 | $46.47 |
| Jul 29, 2025 | $45.98 |
| Jul 30, 2025 | $45.13 |
| 4 days before | -3.54% |
| 4 days after | 3.56% |
| On release day | 6.08% |
| Change in period | -0.111% |
| Release date | Oct 29, 2025 |
| Price on release | $39.73 |
| EPS estimate | $0.550 |
| EPS actual | $0.550 |
| Date | Price |
|---|---|
| Oct 23, 2025 | $41.91 |
| Oct 24, 2025 | $41.45 |
| Oct 27, 2025 | $41.19 |
| Oct 28, 2025 | $40.60 |
| Oct 29, 2025 | $39.73 |
| Oct 30, 2025 | $39.94 |
| Oct 31, 2025 | $40.08 |
| Nov 03, 2025 | $39.81 |
| Nov 04, 2025 | $40.14 |
| 4 days before | -5.20% |
| 4 days after | 1.03% |
| On release day | 0.529% |
| Change in period | -4.22% |
| Release date | Feb 25, 2026 |
| Price on release | $36.89 |
| EPS estimate | $0.570 |
| EPS actual | $0.510 |
| EPS surprise | -10.53% |
| Date | Price |
|---|---|
| Feb 19, 2026 | $37.53 |
| Feb 20, 2026 | $37.63 |
| Feb 23, 2026 | $37.34 |
| Feb 24, 2026 | $37.25 |
| Feb 25, 2026 | $36.89 |
| Feb 26, 2026 | $33.63 |
| Feb 27, 2026 | $32.53 |
| Mar 02, 2026 | $33.62 |
| Mar 03, 2026 | $34.29 |
| 4 days before | -1.71% |
| 4 days after | -7.05% |
| On release day | -8.84% |
| Change in period | -8.63% |
| Release date | Apr 22, 2026 |
| Price on release | $29.96 |
| EPS estimate | $0.520 |
| EPS actual | $0.500 |
| EPS surprise | -3.85% |
| Date | Price |
|---|---|
| Apr 16, 2026 | $33.52 |
| Apr 17, 2026 | $34.00 |
| Apr 20, 2026 | $33.53 |
| Apr 21, 2026 | $33.15 |
| Apr 22, 2026 | $29.96 |
| Apr 23, 2026 | $31.09 |
| Apr 24, 2026 | $30.34 |
| Apr 27, 2026 | $30.74 |
| Apr 28, 2026 | $31.74 |
| 4 days before | -10.62% |
| 4 days after | 5.94% |
| On release day | 3.77% |
| Change in period | -5.31% |
AMERISAFE Earnings Call Transcript Summary of Q1 2026
AMERISAFE posted a solid start to 2026 with disciplined underwriting and continued premium growth. Net premiums earned rose 9% year-over-year, gross premiums written were $88.5 million (up 5.6%), and net earned premiums were $75.1 million. The company delivered a combined ratio of 93.2% and operating earnings of $0.50 per diluted share (GAAP net income $0.43 per share). Retention on renewals remained strong at 92.4%, and new + renewal voluntary premium increased 8.2%, driven by distribution investments and consistent performance across industry classes and states. Current accident year loss ratio was 72%, with $7.6 million (10.1 points) of favorable prior-year development contributing to a net loss ratio of 61.9%. Expense ratio improved to 29.7% (third consecutive year-over-year improvement). Investment yield on new money rose, tax-equivalent yield reached 3.9%, portfolio duration was 4.4 years, and the company repurchased ~120,000 shares for $4.0 million (remaining authorization $12.9 million). Book value per share was $13.18 and invested assets plus cash totaled approximately $774 million. Management emphasized that success depends on disciplined pricing and risk selection amid a prolonged soft pricing environment and ongoing medical claim severity, but believes AMERISAFE’s focused strategy and operating model position it to deliver sustainable underwriting profitability and long-term shareholder value.
Sign In
Buy AMSF